Total Payments
$2,119
2024 Payments
$463.94
Companies
5
Transactions
21
Payment Breakdown by Category
Research$1,252 (59.1%)
Food & Beverage$464.94 (21.9%)
Travel$327.26 (15.4%)
Education$74.99 (3.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1,252 | 13 | 59.1% |
| Food and Beverage | $464.94 | 6 | 21.9% |
| Travel and Lodging | $327.26 | 1 | 15.4% |
| Education | $74.99 | 1 | 3.5% |
Payments by Type
Research
$1,252
13 transactions
General
$867.19
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $1,252 | 13 | $0 (2019) |
| Fresenius USA Marketing, Inc. | $738.57 | 4 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $74.99 | 1 | $0 (2019) |
| NxStage Medical, Inc. | $29.81 | 2 | $0 (2019) |
| BAXTER HEALTHCARE | $23.82 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $463.94 | 2 | Fresenius USA Marketing, Inc. ($463.94) |
| 2021 | $274.63 | 2 | Fresenius USA Marketing, Inc. ($274.63) |
| 2019 | $1,365 | 16 | Gilead Sciences, Inc. ($1,252) |
| 2018 | $15.47 | 1 | NxStage Medical, Inc. ($15.47) |
All Payment Transactions
21 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Fresenius USA Marketing, Inc. | — | Travel and Lodging | Cash or cash equivalent | $327.26 | General |
| 12/12/2024 | Fresenius USA Marketing, Inc. | — | Food and Beverage | In-kind items and services | $136.68 | General |
| 11/03/2021 | Fresenius USA Marketing, Inc. | — | Food and Beverage | In-kind items and services | $52.56 | General |
| 07/13/2021 | Fresenius USA Marketing, Inc. | — | Food and Beverage | In-kind items and services | $222.07 | General |
| 12/13/2019 | Mallinckrodt Enterprises LLC | ACTHAR (Biological) | Education | In-kind items and services | $74.99 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 09/24/2019 | BAXTER HEALTHCARE | Renal - HD (Device) | Food and Beverage | In-kind items and services | $23.82 | General |
| Category: Renal | ||||||
| 09/14/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $64.00 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | ||||||
| 09/14/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $16.24 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | ||||||
| 09/13/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $47.90 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | ||||||
| 09/13/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $47.90 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | ||||||
| 09/13/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $41.39 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | ||||||
| 09/13/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $18.31 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | ||||||
| 09/13/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $17.23 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | ||||||
| 09/13/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $10.88 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | ||||||
| 09/12/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $108.06 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | ||||||
| 09/12/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $23.65 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | ||||||
| 09/12/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $16.24 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | ||||||
| 09/10/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $245.35 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | ||||||
| 08/01/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $594.60 | Research |
| Study: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | ||||||
| 01/31/2019 | NxStage Medical, Inc. | SYSTEM ONE (Device) | Food and Beverage | In-kind items and services | $14.34 | General |
| Category: Nephrology | ||||||
| 02/27/2018 | NxStage Medical, Inc. | System One (Device) | Food and Beverage | Cash or cash equivalent | $15.47 | General |
| Category: Nephrology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | Gilead Sciences, Inc. | $1,252 | 13 |
About Dr. Michael Anger, MD
Dr. Michael Anger, MD is a Nephrology healthcare provider based in Westminster, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1720079205.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Anger, MD has received a total of $2,119 in payments from pharmaceutical and medical device companies, with $463.94 received in 2024. These payments were reported across 21 transactions from 5 companies. The most common payment nature is "" ($1,252).
Ad
Practice Information
- Specialty Nephrology
- Location Westminster, CO
- Active Since 11/02/2005
- Last Updated 10/22/2008
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1720079205
Products in Payments
- ACTHAR (Biological) $74.99
- Renal - HD (Device) $23.82
- System One (Device) $15.47
- SYSTEM ONE (Device) $14.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Westminster
Dr. Joseph Abdallah, M.d, M.D
Nephrology — Payments: $29,090
Nephrology $29,090
Mrs. Katherine Akers, M.d, M.D
Nephrology — Payments: $756.85
Nephrology $756.85
Ingrid Chang, Md, MD
Nephrology — Payments: $632.88
Nephrology $632.88
Matthew Esson, Md, MD
Nephrology — Payments: $464.60
Nephrology $464.60
Dr. Mokhtar Nasir, Md, MD
Nephrology — Payments: $419.86
Nephrology $419.86
Ms. Robin Bender, Rn, RN
Nephrology — Payments: $48.61
Nephrology $48.61